Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bronchial Basal Cells for COPD
NCT05594303Phase 2Completed
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Nov 2019
- Primary completion
- May 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous bronchial basal cells in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Diffusing capacity of the lung for carbon monoxide at 3 months. Started Nov 2019; status: completed.
02
Drugs
autologous bronchial basal cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05594303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594303.